IDEAYA Biosciences, Inc. stock analysis: shares sit near a two-year high while a -36.4% gross margin and 25/100 quality score drive a Sell signal.
@2026 – All Right Reserved.
Category:
By Region
-
-
Insmed Incorporated stock analysis: revenue up 296.1% with a 90/100 growth score, offset by a -76.9% net margin and a Hold signal from our model.
-
IREN Limited stock analysis: a 68.9% gross margin offset by $4.2B of cash burn, revenue down 26.7%, and a Sell signal from our scoring model.
-
Hut 8 Corp. stock analysis: HUT has run roughly 10x off its two-year low, but a 22/100 Quality score and heavy cash burn make it a model Sell.
-
Aerospace & DefenseUS Stocks
SpaceX Nearly Doubled Its Revenue Again, and the Model Still Cannot Score the Stock
Space Exploration Technologies stock analysis: SpaceX grew revenue 91.9% to $23.0B, but missing Quality data leaves the model unable to score it.
-
Cerebras Systems Inc. stock analysis: CBRS grew revenue 74.3% to $681M, but deep losses and missing valuation data leave the model with no signal.
-
GitLab stock analysis: GTLB posts the strongest Growth score in coverage at 85/100, but the model still rates the stock a Hold overall.